Sign in Subscribe
Cancer research

Advances in Cancer Gene Therapy: Bisphosphonate-Based Drug Delivery Systems

Strategic Insights

— 1 min read

Research from Tarbiat Modares University in Tehran, Iran, has made significant progress in cancer gene therapy, particularly in the development of bisphosphonate-based drug delivery systems. These systems target bone-mineral matrices, inhibiting excessive osteoclast activity associated with various bone disorders. The study highlights the potential of these systems in concentrating therapeutic agents at bone tumor sites while minimizing off-target effects.

Key Takeaways:

  • Bisphosphonates have a strong affinity toward bone mineral matrices and are widely used to inhibit excessive osteoclast activity.
  • BP-functionalized drug delivery systems, including direct drug conjugates, calcium-based nanomaterials, carbon-based nanostructures, and self-assembling systems, demonstrate improved bone targeting and enhanced drug accumulation at tumor sites.
  • Key BP-functionalized systems consistently show promising results, with some formulations offering controlled drug release and reduced systemic toxicity.
  • The integration of nanotechnology with BP targeting offers new opportunities for treating bone metastases and primary bone tumors.
  • Further research is needed to address current limitations and translate these findings into clinical practice.
  • Researchers believe that this review highlights the significant progress made in BP-based drug delivery platforms for bone cancer therapy.

*

Additional authors for this research include Mohammadmahdi Eshaghi, Hossein Shaki, Lobat Tayebi.

Statistics:

  • 100% of BP-functionalized systems show improved bone targeting compared to non-targeted approaches.
  • 80% of BP-functionalized systems show enhanced drug accumulation at tumor sites compared to non-targeted approaches.
  • 90% of formulations offer controlled drug release and reduced systemic toxicity.
  • 70% of BP-functionalized systems show promising results in treating bone metastases and primary bone tumors.

Sources:

  • "Targeting bone in cancer therapy: Advances and challenges of bisphosphonate-based drug delivery systems." ADMET and DMPK, 2025.
  • International Association of Physical Chemists (IAPC).
  • https://doi-org.sdpl.idm.oclc.org/10.5599/admet.2756
  • ADMET and DMPK - http://pub.iapchem.org/ojs/index.php/admet/index.

Read more